The European Medicines Agency (EMA) and health technology experts in Europe have extended a collaboration under which they are examining ways to bridge the gap between how drugs are approved for marketing, and later assessed for reimbursement. ---Subscribe to MedNous to access this article--- Regulation & Policy
